The Secondary Prevention of Small Subcortical Strokes (SPS3) Study
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Small subcortical strokes, also known as lacunar strokes, comprise more than 25% of brain infarcts, and the underlying vasculopathy is the most common cause of vascular cognitive impairment. How to optimally prevent stroke recurrence and cognitive decline in S3 patients is unclear. The aim of the Secondary Prevention of Small Subcortical Strokes study (Trial registration: NCT00059306) is to define strategies for reducing stroke recurrence, cognitive decline, and major vascular events. Methods: Secondary Prevention of Small Subcortical Strokes is a randomised, multicentre clinical trial ( n=3000) being conducted in seven countries, and sponsored by the US NINDS/NIH. Patients with symptomatic small subcortical strokes in the six-months before and an eligible lesion on magnetic resonance imaging are simultaneously randomised, in a 2 × 2 factorial design, to antiplatelet therapy – 325 mg aspirin daily plus 75 mg clopidogrel daily, vs. 325 mg aspirin daily plus placebo, double-blind – and to one of two levels of systolic blood pressure targets –‘intensive’ (<130 mmHg) vs. ‘usual’ (130–149 mmHg). Participants are followed for an average of four-years. Time to recurrent stroke (ischaemic or haemorrhagic) is the primary outcome and will be analysed separately for each intervention. The secondary outcomes are the rate of cognitive decline and major vascular events. The primary and most secondary outcomes are adjudicated centrally by those unaware of treatment assignment. Conclusions: Secondary Prevention of Small Subcortical Strokes will address several important clinical and scientific questions by testing two interventions in patients with recent magnetic resonance imaging-defined lacunar infarcts, which are likely due to small vessel disease. The results will inform the management of millions of patients with this common vascular disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Self-citationBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Cited by
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial
(2013) · The Lancet · doi:10.1016/s0140-6736(13)60852-1 · Cited by 749
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke
The SPS3 Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204133 · Cited by 679
Heart disease as a risk factor for dementia
Hakim, A., Ng, & Turek (2013) · Clinical Epidemiology · doi:10.2147/clep.s30621 · Cited by 229
“The SPS-3 trial should clarify this important issue, since prehypertension with SBP under 140 mmHg is frequently not treated aggressively.(165) Data for an association between statins and the prevention of AD neurodegeneration are mixed.”
Metadata
- Authors
- Benavente, O. R., White, C. L., Pearce, L., Pergola, P., Roldan, A., Benavente, M.-F., Coffey, C., McClure, L. A., Szychowski, J. M., Conwit, R., Heberling, P. A., Howard, G., Bazan, C., Vidal-Pergola, G., Talbert, R., Hart, R. G., & for the SPS3 Investigators
- Venue
- International Journal of Stroke
- Publisher
- SAGE Publications
- Published
- 2011-01-26
- Volume
- 6
- Issue
- 2
- Pages
- 164-175
- ISSN
- 1747-4930 (ISSN-L)
- 1747-4949
- OpenAlex
- W1924841915
- Cited by
- 151
- References
- 17
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Secondary Prevention of Small Subcortical Strokes (SPS3) Study. https://app.cochat.ai/papers/10.1111/j.1747-4949.2010.00573.x
- The paper
- Benavente, O. R., White, C. L., Pearce, L., Pergola, P., Roldan, A., Benavente, M.-F., Coffey, C., McClure, L. A., Szychowski, J. M., Conwit, R., Heberling, P. A., Howard, G., Bazan, C., Vidal-Pergola, G., Talbert, R., Hart, R. G., & for the SPS3 Investigators. (2011). The Secondary Prevention of Small Subcortical Strokes (SPS3) Study. International Journal of Stroke. https://doi.org/10.1111/j.1747-4949.2010.00573.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.